Table 2.
ORs and 95% CIs for associations between plasma MMP1, 3, and 7 quintile and breast cancer risk among women in the Nurses’ Health Study, 1992 – 2000
| Quintile |
P-value, test for trend |
|||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| MMP1, ng/mL | ≤0.88 | 0.89 – 1.46 | 1.47 – 2.12 | 2.13 – 3.34 | >3.34 | |
| All breast cancer cases (796 cases, 796 controls) | ||||||
| Cases/Controls | 173/161 | 176/159 | 140/158 | 160/160 | 147/158 | |
| Simple OR (95% CI)a | 1.0 (ref.) | 1.0 (0.8, 1.4) | 0.8 (0.6, 1.1) | 0.9 (0.7, 1.3) | 0.9 (0.6, 1.2) | 0.28 |
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.1 (0.8, 1.5) | 0.9 (0.6, 1.2) | 1.0 (0.7, 1.3) | 0.9 (0.7, 1.3) | 0.51 |
| ER+ tumors * (585 ER+ cases, 796 controls) | ||||||
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.1 (0.8, 1.5) | 0.9 (0.6, 1.2) | 0.9 (0.6, 1.2) | 0.9 (0.6, 1.3) | 0.31 |
| ER− tumors* (161 ER− cases, 796 controls) | ||||||
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.0 (0.6, 1.8) | 0.8 (0.5, 1.5) | 1.0 (0.6, 1.6) | 0.9 (0.5, 1.5) | 0.61 |
| MMP3, ng/mL | ≤7.95 | 7.96 – 9.70 | 9.71 – 11.57 | 11.58 – 14.03 | >14.03 | |
| All breast cancer cases (792 cases, 792 controls) | ||||||
| Cases/Controls | 161/159 | 155/158 | 169/159 | 144/158 | 163/158 | |
| Simple OR (95% CI)a | 1.0 (ref.) | 1.0 (0.7, 1.3) | 1.1 (0.8, 1.4) | 0.9 (0.7, 1.2) | 1.0 (0.8, 1.4) | 0.95 |
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.0 (0.7, 1.3) | 1.1 (0.8, 1.5) | 0.9 (0.7, 1.3) | 1.1 (0.8, 1.5) | 0.88 |
| ER+ tumors * (581 ER+ cases, 792 controls) | ||||||
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.0 (0.7, 1.3) | 1.0 (0.7, 1.4) | 0.9 (0.6, 1.2) | 1.1 (0.8, 1.6) | 0.75 |
| ER− tumors* (160 ER− cases, 792 controls) | ||||||
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.3 (0.8, 2.3) | 1.4 (0.8, 2.5) | 1.3 (0.7, 2.3) | 1.2 (0.7, 2.2) | 0.50 |
| MMP7, ng/mL | ≤0.64 | 0.65 – 0.82 | 0.83 – 1.01 | 1.02 – 1.29 | >1.29 | |
| All breast cancer cases (800 cases, 800 controls) | ||||||
| Cases/Controls | 137/161 | 159/166 | 164/159 | 182/155 | 158/159 | |
| Simple OR (95% CI)a | 1.0 (ref.) | 1.1 (0.8, 1.6) | 1.2 (0.9, 1.7) | 1.4 (1.0, 2.0) | 1.2 (0.9, 1.7) | 0.14 |
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.1 (0.8, 1.6) | 1.2 (0.9, 1.7) | 1.4 (1.0, 2.0) | 1.2 (0.8, 1.7) | 0.18 |
| ER+ tumors * (586 ER+ cases, 800 controls) | ||||||
| Multivariate OR (95% CI)b | 1.0 (ref.) | 1.2 (0.8, 1.6) | 1.2 (0.9, 1.7) | 1.3 (0.9, 1.8) | 1.1 (0.8, 1.6) | 0.40 |
| ER− tumors * (163 ER− cases, 800 controls) | ||||||
| Multivariate OR (95% CI)b | 1.0 (ref.) | 0.9 (0.5, 1.5) | 1.3 (0.8, 2.3) | 1.4 (0.8, 2.4) | 1.2 (0.7, 2.2) | 0.22 |
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; MMP, matrix metalloproteinase
Conditional logistic regression conditioning on matching factors (age at blood draw, date and time of blood draw, fasting status at blood draw, menopausal status at blood draw, and postmenopausal hormone use at blood draw)
Multivariate polytomous logistic regression adjusting for matching factors and body mass index at blood draw (continuous), age at menarche (<12 years, 12 years, 13 years, ≥14 years), alcohol consumption in 1990 (continuous), postmenopausal hormone use (premenopausal, postmenopausal never use, past use, current use <5 years, current use ≥5 years), age at first birth/parity (nulliparous, 1–4 children with age at first birth <25 years, 1–4 children with age at first birth 25–29 years, 1–4 children with age at first birth ≥30 years, ≥5 children with age at first birth <25years, ≥5 children with age at first birth ≥25 years), family history of breast cancer (yes/no), and history of benign breast disease (yes/no)
p-heterogeneity, ER+ vs. ER− breast cancer; MMP1: 0.89, MMP3: 0.64, MMP7: 0.50